Why the study?
Clinical efficacy of omega-3 fatty acids remains inconsistent, potentially due to limited tissue bioavailability, while myocardial incorporation may be essential for reversing structural damage in heart failure.
Does nanoemulsion-based delivery of omega-3 fatty acids improve cardiac uptake and functional outcomes in a murine HFpEF model compared to conventional omega-3 oil?
Population
C57BL/6J mice with diet- and L-NAME-induced HFpEF
Comparison
Nanoformulation NG-Omega-3 vs conventional omega-3 oil
Design
Preclinical animal study
Follow-up
10 weeks
Key result
Nanoemulsion-formulated omega-3 fatty acids increased myocardial accumulation, reduced fibrosis, and improved diastolic function compared to conventional omega-3 in a murine HFpEF model.
Authors
Loading...
Hypothesis-generating for nanoemulsion omega-3 in HFpEF; leaves open clinical translation pending human trials.
Does nanoemulsion-based delivery of omega-3 fatty acids improve cardiac uptake and functional outcomes in a murine HFpEF model compared to conventional omega-3 oil?
Nanoemulsion delivery enhances myocardial bioavailability of omega-3 fatty acids and improves structural remodeling and diastolic function in a murine HFpEF model.
Frid et al. (2026) studied this question. Nanoemulsion-formulated omega-3 fatty acids increased myocardial accumulation, reduced fibrosis, and improved diastolic function compared to conventional omega-3 in a murine HFpEF model.